GeneFerm Biotechnology Balance Sheet Health
Financial Health criteria checks 4/6
GeneFerm Biotechnology has a total shareholder equity of NT$785.2M and total debt of NT$187.1M, which brings its debt-to-equity ratio to 23.8%. Its total assets and total liabilities are NT$1.2B and NT$383.2M respectively.
Key information
23.8%
Debt to equity ratio
NT$187.07m
Debt
| Interest coverage ratio | n/a |
| Cash | NT$136.80m |
| Equity | NT$785.18m |
| Total liabilities | NT$383.16m |
| Total assets | NT$1.17b |
Financial Position Analysis
Short Term Liabilities: 1796's short term assets (NT$429.1M) exceed its short term liabilities (NT$153.7M).
Long Term Liabilities: 1796's short term assets (NT$429.1M) exceed its long term liabilities (NT$229.4M).
Debt to Equity History and Analysis
Debt Level: 1796's net debt to equity ratio (6.4%) is considered satisfactory.
Reducing Debt: 1796's debt to equity ratio has reduced from 112.3% to 23.8% over the past 5 years.
Debt Coverage: 1796's debt is not well covered by operating cash flow (14%).
Interest Coverage: Insufficient data to determine if 1796's interest payments on its debt are well covered by EBIT.